Martin Jasmin E, Nguyen TrangKimberly T, Grunseich Christopher, Nofziger Jonathan H, Lee Philip R, Fields Douglas, Fischbeck Kenneth H, Foran Emily
Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, and.
Section on Nervous System Development and Plasticity, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.
J Neurosci. 2017 May 24;37(21):5309-5318. doi: 10.1523/JNEUROSCI.3472-16.2017. Epub 2017 Apr 27.
Spinal muscular atrophy (SMA) is an autosomal-recessive disorder characterized by severe, often fatal muscle weakness due to loss of motor neurons. SMA patients have deletions and other mutations of the () gene, resulting in decreased SMN protein. Astrocytes are the primary support cells of the CNS and are responsible for glutamate clearance, metabolic support, response to injury, and regulation of signal transmission. Astrocytes have been implicated in SMA as in in other neurodegenerative disorders. Astrocyte-specific rescue of SMN protein levels has been shown to mitigate disease manifestations in mice. However, the mechanism by which SMN deficiency in astrocytes may contribute to SMA is unclear and what aspect of astrocyte activity is lacking is unknown. Therefore, it is worthwhile to identify defects in SMN-deficient astrocytes that compromise normal function. We show here that SMA astrocyte cultures derived from mouse spinal cord of both sexes are deficient in supporting both WT and SMN-deficient motor neurons derived from male, female, and mixed-sex sources and that this deficiency may be mitigated with secreted factors. In particular, SMN-deficient astrocytes have decreased levels of monocyte chemoactive protein 1 (MCP1) secretion compared with controls and MCP1 restoration stimulates outgrowth of neurites from cultured motor neurons. Correction of MCP1 deficiency may thus be a new therapeutic approach to SMA. Spinal muscular atrophy (SMA) is caused by the loss of motor neurons, but astrocyte dysfunction also contributes to the disease in mouse models. Monocyte chemoactive protein 1 (MCP1) has been shown to be neuroprotective and is released by astrocytes. Here, we report that MCP1 levels are decreased in SMA mice and that replacement of deficient MCP1 increases differentiation and neurite length of WT and SMN-deficient motor-neuron-like cells in cell culture. This study reveals a novel aspect of astrocyte dysfunction in SMA and indicates a possible approach for improving motor neuron growth and survival in this disease.
脊髓性肌萎缩症(SMA)是一种常染色体隐性疾病,其特征是由于运动神经元丧失导致严重的、通常致命的肌肉无力。SMA患者存在()基因的缺失和其他突变,导致SMN蛋白减少。星形胶质细胞是中枢神经系统的主要支持细胞,负责谷氨酸清除、代谢支持、损伤反应和信号传递调节。与其他神经退行性疾病一样,星形胶质细胞也与SMA有关。已证明星形胶质细胞特异性恢复SMN蛋白水平可减轻小鼠的疾病表现。然而,星形胶质细胞中SMN缺乏可能导致SMA的机制尚不清楚,星形胶质细胞活性缺乏的具体方面也未知。因此,确定SMN缺乏的星形胶质细胞中损害正常功能的缺陷是值得的。我们在此表明,来自两性小鼠脊髓的SMA星形胶质细胞培养物在支持来自雄性、雌性和混合性别的野生型和SMN缺乏的运动神经元方面存在缺陷,并且这种缺陷可能通过分泌因子得到缓解。特别是,与对照组相比,SMN缺乏的星形胶质细胞单核细胞趋化蛋白1(MCP1)分泌水平降低,MCP1的恢复刺激了培养的运动神经元神经突的生长。因此,纠正MCP1缺乏可能是SMA的一种新治疗方法。脊髓性肌萎缩症(SMA)是由运动神经元丧失引起的,但在小鼠模型中,星形胶质细胞功能障碍也会导致该疾病。单核细胞趋化蛋白1(MCP1)已被证明具有神经保护作用,且由星形胶质细胞释放。在此,我们报告SMA小鼠中MCP1水平降低,补充缺乏的MCP1可增加细胞培养中野生型和SMN缺乏的运动神经元样细胞的分化和神经突长度。这项研究揭示了SMA中星形胶质细胞功能障碍的一个新方面,并指出了改善该疾病中运动神经元生长和存活的一种可能方法。